Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 EMD Millipore, Julphar in Diabetes Pact | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

EMD Millipore, Julphar in Diabetes Pact

Millipore to sell Julphar’s recombinant human insulin

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

EMD Millipore, the Life Science division of Merck KGaA, has entered an exclusive agreement to sell recombinant human insulin manufactured by Julphar Diabetes, a pharmaceutical production company based in the United Arab Emirates. The insulin is of non-animal origin and will be marketed under EMD Millipore’s CellPrime brand. CellPrime Insulin stimulates the proliferation of cells and aids in carbohydrate metabolism, helping to ensure the long-term viability of various cell lines, according to an EMD Millipore statement.
 
“CellPrime Insulin will help the biopharmaceutical industry enhance cell culture performance without sacrificing safety,” said Burghard Freiberg, senior vice president Pharm Chemicals Solutions. “Owing to its non-animal origin, its consistent manufacturing process and the traceability of its raw materials it enables manufacturers of monoclonal antibodies and recombinant biologics to use an insulin supplement that is both safe and effective.”
 
Joe Saldanha, general manger of Julphar Diabetes, said, “This agreement marks a significant achievement for Julphar Diabetes and demonstrates the global impact that the state of the art manufacturing facility is set to make on the diabetes drug industry worldwide. We are proud to be associated with such a strong partner in the life science sector.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters